Vaxcell’s NK Cell Therapy Combo Shows Phase IIa Promise In HCC
But Analyst Sees Need For Further Data
Executive Summary
Korean bioventure’s interim Phase IIa data for locoregional high-dose, autologous natural killer cell therapy in hepatocellular carcinoma in combination with HAIC look "promising," but further safety data awaited.